Skip to content

Study · Animal study (in vivo) · mouse · 2026

20 results

Kisspeptin-54 attenuates acute lung injury in septic mice through AMPK-mediated suppression of NLRP3 inflammasome.

Wang X, Zou Z, Huang H

Neuropeptides23 Jun 2026

PMID42418889 (opens in a new tab)DOI10.1016/j.npep.2026.102639 (opens in a new tab)PepBankPUB-42418889
Publisher pagePubMedAsk about this study
Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

18 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In septic mice, exogenous kisspeptin‑54 improved 7-day survival.

    In plain wordsIn septic mice, kisspeptin‑54 improved survival over 7 days.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Increase7-day survival
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous kisspeptin-54 improved 7-day survival
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In septic mice, exogenous kisspeptin‑54 lowered clinical severity scores.

    In plain wordsIn septic mice, kisspeptin‑54 lowered the clinical severity score.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseClinical severity score
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous kisspeptin-54 improved 7-day survival, lowered clinical severity scores
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In septic mice, exogenous kisspeptin‑54 attenuated lung injury.

    In plain wordsIn septic mice, kisspeptin‑54 reduced lung injury.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseLung injury
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous kisspeptin-54 improved 7-day survival, lowered clinical severity scores, and attenuated lung injury
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In septic mice, exogenous kisspeptin‑54 reduced peritoneal inflammatory cell infiltration.

    In plain wordsIn septic mice, kisspeptin‑54 reduced the number of inflammatory cells in the abdominal cavity.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreasePeritoneal inflammatory cell infiltration
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous kisspeptin-54 improved 7-day survival, lowered clinical severity scores, and attenuated lung injury, as shown by reduced peritoneal inflammatory cell infiltration
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In septic mice, exogenous kisspeptin‑54 decreased pulmonary vascular leakage.

    In plain wordsIn septic mice, kisspeptin‑54 reduced leakage from lung blood vessels.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreasePulmonary vascular leakage
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous kisspeptin-54 improved 7-day survival, lowered clinical severity scores, and attenuated lung injury, as shown by reduced peritoneal inflammatory cell infiltration, decreased pulmonary vascular leakage
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In septic mice, exogenous kisspeptin‑54 decreased pulmonary edema.

    In plain wordsIn septic mice, kisspeptin‑54 reduced lung swelling from fluid.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreasePulmonary edema
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous kisspeptin-54 improved 7-day survival, lowered clinical severity scores, and attenuated lung injury, as shown by reduced peritoneal inflammatory cell infiltration, decreased pulmonary vascular leakage and edema
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In septic mice, exogenous kisspeptin‑54 lowered IL-1β levels.

    In plain wordsIn septic mice, kisspeptin‑54 lowered the inflammatory signal IL-1β.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseIL-1β level
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous kisspeptin-54 improved 7-day survival, lowered clinical severity scores, and attenuated lung injury, as shown by reduced peritoneal inflammatory cell infiltration, decreased pulmonary vascular leakage and edema, and lower IL-1β
    2 context sentences
    Summary · context
    lower IL-1β and IL-18 levels.
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In septic mice, exogenous kisspeptin‑54 lowered IL-18 levels.

    In plain wordsIn septic mice, kisspeptin‑54 lowered the inflammatory signal IL-18.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseIL-18 level
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous kisspeptin-54 improved 7-day survival, lowered clinical severity scores, and attenuated lung injury, as shown by reduced peritoneal inflammatory cell infiltration, decreased pulmonary vascular leakage and edema, and lower IL-1β and IL-18 levels.
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In septic mice, kisspeptin‑54 suppressed NLRP3 in lung tissue.

    In plain wordsIn septic mice, kisspeptin‑54 lowered NLRP3, an inflammation driver, in the lung.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseNLRP3 in lung tissue
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, kisspeptin-54 suppressed NLRP3 inflammasome components (NLRP3, ASC, cleaved caspase-1) in lung tissue
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In septic mice, kisspeptin‑54 suppressed ASC in lung tissue.

    In plain wordsIn septic mice, kisspeptin‑54 lowered ASC, an inflammation protein, in the lung.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseASC in lung tissue
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, kisspeptin-54 suppressed NLRP3 inflammasome components (NLRP3, ASC, cleaved caspase-1) in lung tissue
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In septic mice, kisspeptin‑54 suppressed cleaved caspase-1 in lung tissue.

    In plain wordsIn septic mice, kisspeptin‑54 lowered active caspase-1, an inflammation enzyme, in the lung.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseCleaved caspase-1 in lung tissue
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, kisspeptin-54 suppressed NLRP3 inflammasome components (NLRP3, ASC, cleaved caspase-1) in lung tissue
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In septic mice, kisspeptin‑54 enhanced AMPK phosphorylation in lung tissue.

    In plain wordsIn septic mice, kisspeptin‑54 increased activation of AMPK in the lung.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseAMPK phosphorylation in lung tissue
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Receptor activity and mechanism · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, kisspeptin-54 suppressed NLRP3 inflammasome components (NLRP3, ASC, cleaved caspase-1) in lung tissue while enhancing AMPK phosphorylation.
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  13. 13AnimalAnimal study (in vivo)Mechanism

    In septic mice, kisspeptin‑54 curbed pulmonary neutrophil accumulation preferentially over macrophages.

    In plain wordsIn septic mice, kisspeptin‑54 reduced neutrophils in the lung more than macrophages.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreasePulmonary neutrophil accumulation compared with macrophages
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Kisspeptin-54 preferentially curbs pulmonary neutrophil accumulation over macrophages.
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  14. 14AnimalAnimal study (in vivo)Safety outcome

    In healthy mice, therapeutic doses of kisspeptin‑54 alone were non-toxic.

    In plain wordsIn healthy mice, kisspeptin‑54 alone at therapeutic doses was not toxic.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changeToxicity of therapeutic kisspeptin-54 doses in healthy animals
    Study

    mousen: not reported in source

    healthy mice
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Baseline toxicity screening confirmed that therapeutic doses of Kisspeptin-54 alone are entirely non-toxic in healthy animals
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.
  15. 15LabIn vitro (cells)Mechanism

    In murine alveolar macrophage MH-S cells, kisspeptin‑54 enhanced AMPK phosphorylation.

    In plain wordsIn mouse lung immune cells, kisspeptin‑54 increased activation of AMPK.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseAMPK phosphorylation in MH-S cells
    Study

    mousen: not reported in source

    murine alveolar macrophage cell line MH-S
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    cell-autonomous validation using the validated murine alveolar macrophage cell line MH-S confirmed that Kisspeptin-54 directly enhances AMPK phosphorylation
  16. 16LabIn vitro (cells)Mechanism

    In murine alveolar macrophage MH-S cells, kisspeptin‑54 reduced NLRP3 expression by 48%.

    In plain wordsIn mouse lung immune cells, kisspeptin‑54 lowered NLRP3 by 48%.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseNLRP3 expression in MH-S cells
    Study

    mousen: not reported in source

    murine alveolar macrophage cell line MH-S
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    NLRP3 expression reduction
    48%
    MH-S cells

    Source sentences

    Summary
    cell-autonomous validation using the validated murine alveolar macrophage cell line MH-S confirmed that Kisspeptin-54 directly enhances AMPK phosphorylation, reduces NLRP3 expression by 48%
  17. 17LabIn vitro (cells)Mechanism

    In murine alveolar macrophage MH-S cells, kisspeptin‑54 suppressed cleaved caspase-1 maturation by 52%.

    In plain wordsIn mouse lung immune cells, kisspeptin‑54 lowered caspase-1 activation by 52%.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseCleaved caspase-1 maturation in MH-S cells
    Study

    mousen: not reported in source

    murine alveolar macrophage cell line MH-S
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Cleaved caspase-1 maturation reduction
    52%
    MH-S cells

    Source sentences

    Summary
    cell-autonomous validation using the validated murine alveolar macrophage cell line MH-S confirmed that Kisspeptin-54 directly enhances AMPK phosphorylation, reduces NLRP3 expression by 48%, and suppresses cleaved caspase-1 maturation by 52%
  18. 18LabIn vitro (cells)Mechanism

    In murine alveolar macrophage MH-S cells, kisspeptin‑54 curbed IL-1β release into the supernatant.

    In plain wordsIn mouse lung immune cells, kisspeptin‑54 reduced release of IL-1β.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseIL-1β release from MH-S cells
    Study

    mousen: not reported in source

    murine alveolar macrophage cell line MH-S
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    cell-autonomous validation using the validated murine alveolar macrophage cell line MH-S confirmed that Kisspeptin-54 directly enhances AMPK phosphorylation, reduces NLRP3 expression by 48%, and suppresses cleaved caspase-1 maturation by 52%, thereby curbing supernatant IL-1β release

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 19AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In mice with cecal ligation and puncture sepsis, circulating kisspeptin‑54 was reduced.

    In plain wordsIn septic mice, the body's own kisspeptin‑54 in the blood was lower.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseCirculating kisspeptin-54 during sepsis
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54

    This result measures the body's own Kisspeptin-54 (metastin). Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone1

In this study, Kisspeptin-54 (metastin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-54 (metastin).

  1. 20AnimalNot a test of Kisspeptin-54 (metastin) aloneAnimal study (in vivo)Mechanism

    In septic mice, the AMPK inhibitor compound C reversed the protective effects of kisspeptin‑54.

    In plain wordsIn septic mice, blocking AMPK with compound C reversed the protective effects of kisspeptin‑54.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseKisspeptin-54 protective effects with AMPK inhibitor compound C
    Study

    mousen: not reported in source

    cecal ligation and puncture (CLP) septic mouse model
    Outcome group
    Receptor activity and mechanism · Respiratory

    Source sentences

    Summary
    These protective effects were reversed by the AMPK inhibitor compound C.
    1 context sentence
    Summary · context
    In a cecal ligation and puncture (CLP) mouse model, we observed reduced circulating kisspeptin-54 and downregulated pulmonary GPR54 expression during sepsis.

    In this study, Kisspeptin-54 (metastin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-54 (metastin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.